CVRx, Inc.

CVRx, Inc. is a commercial-stage medical device company headquartered in Minneapolis, Minnesota, dedicated to developing, manufacturing, and commercializing innovative neuromodulation solutions for cardiovascular diseases. Incorporated in Delaware in August 2000, the company's mission is to advance device therapies that modulate the autonomic nervous system, aiming to significantly improve the lives of individuals with chronic conditions.

The company's primary product is the Barostim™ System, which delivers Baroreflex Activation Therapy (BAT). This implantable device sends electrical pulses to baroreceptors in the carotid artery, activating the body's natural reflex to regulate cardiovascular function. Barostim is the first medical technology approved by the FDA that uses neuromodulation to improve symptoms in patients with systolic heart failure and is also approved for resistant hypertension in other regions.

Recent developments include the appointment of Kevin Hykes as President and CEO in February 2024. CVRx initiated the BENEFIT-HF randomized trial in January 2026 to evaluate Barostim in an expanded heart failure population, and new Category I CPT codes for Barostim therapy became effective, aiming to improve reimbursement. The company reported preliminary first-quarter 2026 revenue of $14.7 million to $14.8 million, reflecting approximately 20% growth compared to the first quarter of 2025, and full-year 2025 revenue of $56.7 million.